- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Encouraging Findings on Lung Cancer Rates in the US
Although the overall rate of NSCLC is lower, certain subtypes of the disease fared better than others, the study published in the journal Cancer found.
Overall lung cancer rates are dropping, according to a new analysis of nearly a half million Americans with lung cancer. But, the news wasn't all good -- the study also found that the rates of certain types of lung cancer are increasing, according to researchers from the U.S. National Cancer Institute (NCI).
Over nearly three decades, the overall lung cancer rate has dropped approximately 12 percent, said the study's lead author Denise Riedel Lewis, an epidemiologist at the NCI.
"The good news is that lung cancer rates are declining. However, it's not as clear for certain subtypes, and we are not exactly sure of the reasons behind these increases," Riedel Lewis said.
Riedel Lewis said that while she cannot draw a definitive conclusion about what's causing the decline in lung cancer rates, she can infer that it's mostly due to decreases in smoking.
Original report: http://bit.ly/1uHdGy0
Source: Philly
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
